Key Highlights

  • Reports of $400bn Merger talks with Bristol Myers Squibb were denied within days by a source close to the matter
  • Half-year Revenue reached $30,672m, up 9% at actual rates and 6% at constant currency
  • Core Earnings Per Share rose 12% to $5.21, with the core Operating Margin holding at 34%
  • The board lifted the Interim Dividend by three cents to $1.06 a share
  • Full-year 2026 guidance was reconfirmed, targeting mid-to-high single-digit revenue growth and low double-digit core EPS growth

For roughly seventy-two hours in early August, the City entertained the idea that Britain's most valuable listed company was about to disappear into the largest pharmaceutical merger in history. The Financial Times reported that AstraZeneca (LSE:AZN) had held talks with New York's Bristol Myers Squibb about a combination valued at more than $400bn. Shares lurched lower, analysts scrambled, and headline writers reached for superlatives. Then, almost as quickly, the story unravelled: Reuters cited a senior source insisting there was no deal, no discussions and, pointedly, that there never was a deal to be done. Investors are left weighing a strong set of half-year numbers against a company whose centre of gravity is drifting steadily westward.

Company and news background

AstraZeneca is the FTSE 100's heavyweight, an Anglo-Swedish drugmaker with a Market Value of roughly £200bn and a Business built on oncology, cardiovascular and respiratory medicines. Under chief executive Pascal Soriot it has grown into one of the world's five largest pharmaceutical companies by revenue.

The merger episode ran fast. On the weekend of 2--3 August the FT reported exploratory talks with Bristol Myers Squibb that, if consummated, would have created the world's fourth-largest drugmaker. AstraZeneca declined to comment. AZN shares fell sharply on the news — down close to 9% at one point — before recovering ground. By Wednesday 5 August, Reuters had reported a flat denial from a source close to the matter, and the stock rebounded roughly 3%. Bristol Myers shares, which had wobbled, slipped about 3% on the retraction.

The reaction from analysts was less excitement than bafflement. Jefferies argued AstraZeneca had no need for financial engineering; Citi called the reported approach a surprise given the strength of the pipeline. IG's Chris Beauchamp flagged the obvious problem: two enormous cancer franchises sitting side by side would have been a magnet for antitrust reviewers, not least under a Trump administration already scrutinising big deals.

The numbers that matter

Strip away the deal noise and the underlying business is performing. AstraZeneca's half-year results, published in late July, showed total revenue of $30,672m, up 9% at actual rates and 6% at constant currency. Core earnings per share reached $5.21, an increase of 12%, while reported EPS came in at $3.60. The core operating margin held at 34%.

Second-quarter revenue was $15,384m, up 6%, with core EPS of $2.63, up 21% year on year. The board lifted the interim dividend by three cents to $1.06 a share, equivalent to 79.5 pence.

Crucially, management reconfirmed full-year 2026 guidance: total revenue growth in the mid-to-high single digits and core EPS growth in the low double digits, with a core tax rate of 18--22%. The company also restated its headline ambition of $80bn in total revenue by 2030 — the target that makes the notion of a defensive megamerger look, to its detractors, unnecessary.

What is driving the story

Two threads run beneath the merger flurry. The first is Bristol Myers Squibb's own predicament. The US group faces looming Patent cliffs on blockbusters including Opdivo and the blood thinner Eliquis, with generic competition anticipated later this decade. A tie-up would have handed AstraZeneca scale in oncology but also imported those exclusivity risks — one reason the strategic logic left analysts cold. AstraZeneca's oncology arm already generates around $25bn a year, close to half of group revenue, so the overlap with Bristol Myers' cancer-heavy portfolio was substantial.

The second thread is AstraZeneca's steady Americanisation. In February the company completed a direct listing of its ordinary shares on the New York Stock Exchange, switching its US quote from Nasdaq while keeping London as its primary listing. That followed reporting in 2025 that Soriot had privately weighed moving the primary listing across the Atlantic altogether, amid frustration with UK drug pricing — the NICE rejection of breast-cancer therapy Enhertu being a sore point — and the pull of a larger, better-paying US market. A multibillion-dollar US Manufacturing and Investment programme has reinforced the tilt. Against that backdrop, even denied merger talks fed a familiar anxiety in Westminster: that Britain's corporate crown jewel is being courted, and courting, away from home.

What it means for investors

The bull case is straightforward. AstraZeneca is compounding revenue at a mid-to-high single-digit clip, expanding margins, raising the dividend and reaffirming an $80bn revenue goal, all without needing to bet the company on a transformational acquisition. A deep late-stage pipeline — Soriot pointed to several positive Phase III readouts and multiple first approvals in the half — underpins the growth story, with cardiovascular candidate baxdrostat among the Assets watched closely.

The bear case is about concentration and disappointment risk. Oncology dominates the top line, so any clinical or regulatory stumble bites hard. The pipeline has not been uniformly kind this year: there have been late-stage setbacks alongside the wins, and the market has punished individual trial misses with double-digit single-day share moves. Valuation is full rather than cheap, leaving little margin for error. And the governance question — whether the primary listing ultimately migrates to New York — hangs over UK-based holders, with implications for index inclusion and sterling exposure.

On competitive position, AstraZeneca remains among the strongest franchises in global oncology. The Balance Sheet is robust enough to fund both the dividend and continued bolt-on dealmaking. What the merger reports underlined is that the company can plausibly reach its targets organically; the strategic debate is about domicile and listing, not survival.

What comes next

The near-term catalysts are clinical and regulatory. Investors will watch further Phase III data readouts across oncology and cardiovascular programmes, US regulatory decisions on pending filings, and the third-quarter results due in the autumn, when management will either reinforce or temper the full-year guidance. The longer-running question is the listing: any concrete move toward a US primary quote would be market-moving and politically charged. And while a Bristol Myers deal has been firmly denied, the episode is a reminder that speculation around large-cap pharma consolidation is unlikely to fade.

The takeaway is that the fundamentals and the narrative have decoupled. AstraZeneca's operating performance is doing the quiet work of a well-run megacap, while its strategic identity — how American it wants to become, and where its shares should trade — generates the noise. The merger that never was told investors little about the company's needs and a great deal about the market's appetite to imagine its reinvention. For now, the more consequential story is not a $400bn transaction but the slow gravitational pull of the United States on a company still headquartered and primarily listed in Britain.